• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Pharmaceutical Marketing - Whats in store for patients?
 

Pharmaceutical Marketing - Whats in store for patients?

on

  • 1,817 views

 

Statistics

Views

Total Views
1,817
Views on SlideShare
1,817
Embed Views
0

Actions

Likes
2
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Pharmaceutical Marketing - Whats in store for patients? Pharmaceutical Marketing - Whats in store for patients? Document Transcript

    • Sponsored by:WHITEPAPERPharmaceuticalMarketingTargetingconsumers.Connectingonline.What’sinstoreforpatients.20111017-WHTP--0001-NAT-CCI-AA_-- 10/18/2011 2:11 PM Page 1
    • Project1:Layout 1 10/7/11 11:55 AM Page 1
    • | October 17, 2011 | 3WHITE PAPERMORE ONADAGE.COMThisisoneinaseriesofwhitepaperspublishedbyAdvertisingAge.ToseeotherAdAgewhitepapersandtoobtainadditionalcopiesofthisone,gotoAdAge.com/whitepapers➜Sponsoredby:INTRODUCTIONAd spending:15 years of DTCBYBETHSNYDERBULIKit’s been almost 15 years since U.S. direct-to-consumer adver-tising regulations were loosened.And in those years,the consumerpharmaceuticalmarketingindustryhasgonefromabout$700mil-lion in ad spending to a peak of $5.4 billion in 2006. Spending in2010—about $4.3 billion—was down, but pharmaceutical adver-tising remains a big business.Before 1997, pharma marketers were allowed to name a brandin an ad—but with the onus of the “brief summary,” a summationof side effects, contraindications and effectiveness usually writtentechnically and typically anything but “brief.” Ads appeared inprint,butthesummarymandatewouldhavemadeTVadstoolong.FDAguidance,introducedin1997andformallyadoptedin1999,allowedTV ads to name a pharma brand and the condition it treat-ed without the summary. Instead,TV ads were required to includea “major statement” of the most important risks with a referral toa source of in-depth information.That led to the explosion of DTCadvertising, mostly in TV.Pharma marketing is in flux again. The meteoric rise of digitalinformation and social-media channels, the still-evolving regulato-ry environment, the maturing of mainstream blockbuster drugs,and fewer new drugs being brought to market all point to a majorinflection point in pharmaceutical marketing.Change means new opportunities. Globalization, personalizedmedicines and therapies, the potential for niche drugs, and diversi-fication into broader health-care portfolios are all potentially posi-tive side effects pointed out by the experts interviewed for thiswhite paper.“This industry is in massive transition,”said Nick Colucci,pres-ident-CEO,Publicis Groupe’s Publicis Healthcare CommunicationsGroup. “The health-care industry in general is changing, goingfrom broad-based to targeted therapies. Like any evolution andchange, there are some players that will come out stronger andthere are some that will disappear. … The future is all about prod-ucts that will be more targeted,products that will be used,ultimate-ly, just for you.”What does that mean for advertising and marketing of pharma-ceuticals? It means that will have to change as well. Change isalready happening. Health-care standalone agencies are no longerstandoffish in agency families and instead are being reintegratedinto the larger group or broadened into wider agency networks.WPP’s Grey Group recently created Grey Healthy People, a“specialized unit totally integrated within the overall agency” andmeant to house not only its DTC and over-the-counter clients, butalso broader health-care clients including personal-care productssuch as toothpaste, mouthwash and tampons.TABLEOFCONTENTSADSPENDING:15YEARSOFDTC 3- MEDIASPENDING:1996TO2010 5- LARGESTPHARMAADVERTISERS 6- MEDIASPENDING BYCATEGORY 7- MOST-ADVERTISEDPHARMABRANDS 8- PHARMAADVERTISING BYMEDIUM 9- HEALTH-CAREREFORM 9WEBMARKETINGCHALLENGES 10- TIMESPENTONPHARMASITES 10- LARGESTPHARMAINTERNETADVERTISERS 11SOCIALMEDIAANDHEALTH 13- SHAREOFDISCUSSION- HOWDIABETES-RELATEDBRANDSRESONATEINSOCIALMEDIAPHARMACIESANDPHARMACISTS 14- FIVEMOST-VALUEDSOURCESFORHEALTH-CAREINFORMATION 14- BABYBOOMERSTAKINGONNEWHEALTH-CARERESPONSIBILITIES 15- MOST-PRESCRIBEDPHARMACEUTICALS 16PHARMACYBENEFITSMANAGERS 17- LARGESTFIRMS- PRESCRIPTIONSFILLEDBYPBM- PRESCRIPTIONSFILLEDWITHGENERICSCOMMERCIALTUNEAWAY 18- HOWWELLPHARMACEUTICALADSRETAINVIEWERSEmail: DataCenter@AdAge.com.SendmailtoAdAgeDataCenter,360N.MichiganAve.6thFl.,Chicago,IL60601.Additionalcopies:Orderprintatcustomerservice@adage.com.DigitaleditionavailablefreeonlineatAdAge.com/whitepapers.Adsales:(212)210-0171.This document, and information contained herein, is thecopyrighted property of Crain Communications Inc. andAdvertising Age (Copyright 2011) and is for your personal,non-commercial use only. You may not reproduce, displayon a website, distribute, sell or republish this document, orthe information contained herein, without prior writtenconsent of Advertising Age. Copyright 2011 by CrainCommunicationsInc.Allrightsreserved.CONTACTADAGE1.U.S.DepartmentofHealthandHumanServices.Includesspendingbyconsumers,insurancecompanies,governmentandvariousthirdparties.2.KantarMediafor17measuredmedia.$259BU.S.2010prescriptiondrugcosts1$4.3BU.S.2010prescriptiondrugadspending220111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • AA010745 10/7/11 11:47 AM Page 1
    • Indeed, the agency executives Ad Age interviewed agreed thatthose silos of DTC ad specialists won’t work with the changinglandscape. Most of the industry embraces the idea of broaderhealth-care communications.“The role of agencies as mediator, negotiator, liaison and ulti-matelyambassadorbetweenpharmaceuticalcompanies,thirdpartiesthat have the trust, and academics and researchers thathave the clinical knowledge and understanding … that’swhere we can help usher in that new era.That’s the valuewe can provide,” said Michael Spitz, VP-digital strategy,inVentiv Health’s Ignite Health.AD SPENDING CHANGESU.S. measured-media ad spending by pharmaceuticalmarketers, mostly in the traditional areas of TV andprint with digital claiming only a minor share of whatmost marketers spend, peaked at $5.4 billion in 2006,according to WPP’s Kantar Media. Spending hasdeclined every year since then to $4.3 billion in 2010, adecrease of almost 20% over five years.Year-over-yearad spending from 2009 to 2010 alone dropped 8.8%.Pharmaceutical companies are spending less onmarketing for several reasons including some heavilymarketed drugs that have gone off-patent, a smallerpipeline with fewer new drugs coming to market andmore skeptical consumers. But the main reasonthey’ve cut back is, like many other companies andconsumers in the recession and tepid recovery, theysimply have less to spend.That’s not likely to change anytime soon. Along with fewergroundbreaking mainstream drugs, the dreaded “patent cliff” islooming with even more blockbuster—and heavily marketed—prescription drugs set to lose their patents and go generic.Pfizer’sLipitor leads the pack in November 2011, but it will be followedin 2012 by Bristol-Myers Squibb’s Plavix, Merck’s Singulair,AstraZeneca’s Seroquel, Takeda’s Actos and Forest Laboratories’Lexapro. However, the end of those drugs as brands, while dra-matic, is not a death knell for any company and certainly not theend of the pharma ad industry.“It’s incredibly short-sighted,but a lot of people are saying thesky is falling because Lipitor is going off patent,” said NedRussell,managing director,Publicis Groupe’s Saatchi &Saatchi Wellness. “Yes, some blockbusters are goinggeneric, but there are so many other things going on.There are great opportunities, but it’s just not a $150million ad campaign for Lipitor or Plavix or whatever.It’s more about targeting to patients who have specificneeds. … It’s also about proactive health. It’s more of ajourney where marketing communications plays a rolein advising and helping the consumer along.”IMPERATIVE TO CREATE BRAND VALUEMark Goldstone, president of Omnicom Group’s DDBHealth, said marketing will have to change along withthe industry.The old way,when innovation in the formof a breakthrough drug or treatment sold the product,is gone. Major mainstream breakthroughs are few andfar between. It will be up to agencies to help marketerscreate value.“The difference between the old and the new drugswas great. So the drug rep went into the doctors andexplained that, then took them to lunch, took his wholefamily to Disney, and sales went up,” Mr. Goldstonesaid. “They didn’t have to create value, like bottles ofwater have to.That was created in the lab, and reps would do therest. … Now everyone is under pressure, the new drugs mayonly deliver a small benefit, and the drug rep has to go in andexplain why that justifies the expense. And oh, I can’t leave youa pen anymore, I certainly can’t take you to lunch, and there isdefinitely no Disney.”PHARMACEUTICAL MEDIA SPENDING: 1996 TO 2010ByU.S.measured-mediaadspending.0$61996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009$0.70$0.98$1.31$1.92$2.59$2.82 $2.78$3.45$4.43 $4.65$5.41 $5.18$4.66 $4.772010$4.34-3060%DOLLARS IN BILLIONS PERCENT CHANGE40.3%-8.8%| October 17, 2011 | 5Sponsoredby:PHARMACEUTICAL MARKETINGSource:KantarMedia.Totalsarefor17measuredmedia:networkTV,spotTV,cableTVnetworks,Spanish-languageTVnetworks,syndicatedTV,consumermagazine,Sundaymagazine,Spanish-languagemagazine,localmagazine,newspaper,nationalnewspaper,Spanish-languagenewspaper,nationalspotradio,networkradio,localradio,outdoorandinternetdisplay(excludingsearchandbroadbandvideo).“It’sincrediblyshort-sighted,butalotofpeoplearesayingtheskyisfallingbecauseLipitorisgoingoffpatent.”20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • 6 | October 17, 2011 |WHITE PAPER25 LARGEST PHARMACEUTICAL ADVERTISERSBy2010U.S.measured-mediaadspendingin17media.Dollarsareinmillions.Source:KantarMedia.Totalsarefor17measuredmedia:networkTV,spotTV,cableTVnetworks,Spanish-languageTVnetworks,syndicatedTV,consumermagazine,Sundaymagazine,Spanish-languagemagazine,localmagazine,newspaper,nationalnewspaper,Spanish-languagenewspaper,nationalspotradio,networkradio,localradio,outdoorandinternetdisplay(excludingsearchandbroadbandvideo).MEDIASPENDING MOST-ADVERTISED BRAND’S2010RANK MARKETER 2010 2009 %CHANGE BRAND MEDIASPENDING1. Pfizer,NewYork $967.5 $1,148.6 -15.8 Lipitor $272.02. EliLilly&Co.,Indianapolis 470.8 370.0 27.2 Cialis 220.63. AstraZeneca,London 422.7 388.6 8.8 Symbicort 152.24. GlaxoSmithKline,London 338.6 311.2 8.8 Advair 200.55. Bristol-MyersSquibbCo.,NewYork 330.0 423.6 -22.1 Abilify 155.76. Merck&Co.,WhitehouseStation,N.J. 320.6 460.1 -30.3 Singulair 70.37. Johnson&Johnson,NewBrunswick,N.J. 173.7 88.9 95.3 Simponi 70.18. Allergan,Irvine,Calif. 166.6 137.5 21.2 Restasis 58.09. AbbottLaboratories,AbbottPark,Ill. 143.4 157.5 -9.0 Trilipix 56.310. RocheHolding,Basel,Switzerland 95.9 93.2 3.0 Boniva 85.211. TakedaPharmaceuticalCo.,Osaka,Japan 93.8 2.5 NA Uloric 43.612. Sanofi-Aventis,Paris 92.6 190.0 -51.3 Lantus 46.513. DainipponSumitomoPharmaCo.,Osaka,Japan 89.1 55.0 61.9 Lunesta 54.114. BoehringerIngelheim,Ingelheim,Germany 85.5 193.8 -55.9 SpirivaHandiHaler 70.715. Novartis,Basel,Switzerland 78.2 145.3 -46.2 Reclast 48.216. Shire,Dublin 71.9 84.9 -15.3 Vyvanse 58.017. BayerAGGroup,Leverkusen,Germany 71.8 115.2 -37.7 Yaz 41.518. Amgen/Pfizer,ThousandOaks,Calif. 71.5 91.1 -21.5 Enbrel 71.519. Astellas/GlaxoSmithKline,Tokyo 43.6 38.3 13.9 Vesicare 43.620. Galderma(L’Oreal/Nestle),Lausanne,Switzerland 36.6 57.4 -36.3 Epiduo 26.221. UCB,Brussels 30.4 0.3 NA Cimzia 21.122. TevaPharmaceuticalIndustries,PetachTikva,Israel 27.6 32.6 -15.3 Seasonique 27.423. AuxiliumPharmaceuticals,Malvern,Pa. 18.2 0.0 NA Xiaflex 18.224. FerringPharmaceuticals,Parsippany,N.J. 17.3 0.0 NA Lysteda 9.325. NovoNordisk,Bagsard,Denmark 15.7 2.1 NA Victoza 8.520111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • | October 17, 2011 | 7Sponsoredby:PHARMACEUTICAL MARKETINGInnovation is still there, just in more niche audiences. Cancertreatments, for instance, show promise as areas where drug com-panies can innovate for smaller audiences of patients.REGULATORY ENVIRONMENTExacerbating the market difficulties is the unique posi-tion the pharma industry is in when it comes to feder-al regulations. It is a very regulated industry, fromresearch, development and testing of new drugs tomarketing those drugs.While regulations are there fora good reason, they also are an additional challenge.That’s particularly true now that the consumer worldhas gone totally tech and pharma companies are ham-pered in their efforts, partly by their own concerns ofsanctions and partly by the fact that there are no realguidelines for digital marketing given by the FDA.“How do we become a customer-centric industrywhen we’ve never been one before? Outside of OTC,thefocus in DTC has been on physicians.We’re not a directseller, not an online pharmacy and we’re not sellingTylenol,” said Fabio Gratton, chief innovation officer atIgnite. “A company is a company is a company, but yetpharma has its hands tied a bit.”Pharma companies will have to market online.“Budgets are shrinking, physicians are more skepti-cal and have less time for reps, and pharma has lessmoney to spend. Pharma almost has no choice but toturn away from expensive media channels and embracethe more economical digital channels,” Ignite’s Mr. Spitz said.TRADITIONAL MEDIASo what will happen to TV and print advertising, with their longand sometimes off-putting explanations of side effects and poten-tial problems, when the money moves online in the pharmaceuti-cal industry? Like many other industries where the change hasalready occurred, traditional media will survive. The function ofthose ads may change, though.“TV, magazines and journals will continue to have a role, and itwill still be appropriate to communicate through those media. Butthat focus will be more on the appropriate use, the continued useand adherence (to a prescribed medicine),” DDB’s Mr. Goldstonesaid. “Fewer than 50% of people on cardiovascular products taketheir medicine regularly. … There’s a lot of work to bedone around adherence and compliance. Connect withtheir physicians through advertising or an introductionto a website, then you’re connected, and the CRM (cus-tomer relationship management) connection is made.‘Welcome to the use of the product’ with robust pro-grams behind that.”EMPOWERED PATIENTSPerhaps the biggest challenge pharmaceutical companiesfaceisinbuildingamoredirectrelationshipwiththecon-sumer. Some won’t attempt to do it—whether in fear ofFDA reprisal or a corporate philosophy that they are sci-ence and research companies,not marketers.One agencyexecutive reports a senior pharma executive said—in arecent tweet chat on mobile health—that he believespharma companies should stay out of mobile health adcampaigns entirely.Some pharma marketers have jumped right in.Mr. Gratton pointed to a social-media effort Ignitecreated for Novo Nordisk with the Juvenile DiabetesResearch Foundation to develop a vibrant patient com-munity, Juvenation, a peer-to-peer social group for people withtype 1 diabetes.Launched in November 2008,the community nowhas 14,000 members, according to its Facebook page.“We’ve all heard what’s happening now called things like‘Pharmaggedon,’ but there are also many people who are excitedby all the changes.They’re experimenting,maybe failing,and try-ing again.They’re creating campaigns by listening and opening upchannels and trying everything they can to understand con-sumers today,” Mr. Gratton said.PHARMACEUTICAL AD SPENDING BY CATEGORY IN 2010U.S.measured-mediaadspendingof$4.3billionbycondition.Stomach 1.1% ($49 million)Sleep disorder 1.3%($55 million)Impotence 7.3% ($316 million)Contraceptive 2.7%($116 million)Mental health 14.8%($643 million)Heart, blood pressure andcholesterol 14.3% ($620 million)Allergy, asthma 7.8% ($339 million) Corporate,multi-conditionand other 40.7%($1.77 billion)Arthritis 10.1% ($437 million)Source:KantarMedia.ConditionslistedbasedonKantarMediaclassificationsforprescriptiondrugsandpharmaceuticalhouses.Over-the-countermedicationsareexcluded.Likeotherindustrieswithdigitalmarketinggrowth,traditionalmediawillsurvive.Butthefunctionoftheadsmayneedtochange20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • 8 | October 17, 2011 |WHITE PAPER25 MOST-ADVERTISED PRESCRIPTION DRUGSBy2010U.S.measured-mediaadspendingin17media.Dollarsareinmillions.Source:KantarMedia.Totalsinclude17measuredmedia.RankingbasedonAdAgeDataCenteranalysis.Somepharmabrandsareco-marketed.SeeP.5andP.7fornotesonmeasuredmedia.MEDIASPENDINGRANK PHARMACEUTICAL,MARKETER 2010 2009 %CHANGE PRIMARYCONDITION(S)1. Lipitor,Pfizer $272.0 $247.1 10.1 Highcholesterol2. Cialis,EliLilly&Co. 220.6 179.2 23.1 Erectiledysfunction3. Cymbalta,EliLilly&Co. 206.0 182.7 12.7 Mentalhealth,depression4. Advair,GlaxoSmithKline 200.5 183.3 9.4 Asthma,respiratory5. Abilify,Bristol-MyersSquibbCo. 155.7 205.7 -24.3 Mentalhealth,depression6. Symbicort,AstraZeneca 152.2 136.2 11.8 Asthma,COPD,respiratory7. Pristiq,Pfizer 127.4 124.4 2.4 Mentalhealth,depression8. Plavix,Bristol-MyersSquibbCo. 127.3 149.9 -15.1 Bloodthinner9. Chantix,Pfizer 122.2 155.8 -21.5 Smoking10. Lyrica,Pfizer 112.2 162.2 -30.8 Diabetes,fibromyalgia11. Toviaz,Pfizer 109.5 56.5 93.7 Bladdercontrol12. Viagra,Pfizer 99.9 128.0 -22.0 Erectiledysfunction13. Crestor,AstraZeneca 95.1 129.4 -26.4 Highcholesterol14. Boniva,RocheHolding 85.2 81.6 4.4 Osteoporosis15. Lovaza,GlaxoSmithKline 80.7 6.4 1152.5 Highcholesterol(triglycerides)16. Seroquel,AstraZeneca 80.6 64.2 25.4 Mentalhealth,depression17. Enbrel,Amgen/Pfizer 71.5 85.3 -16.1 Arthritis,psoriasis18. SpirivaHandiHaler,BoehringerIngelheim 70.7 77.6 -8.8 COPD,respiratory19. Singulair,Merck&Co. 70.3 78.1 -10.0 Asthma,allergy,respiratory20. Simponi,Johnson&Johnson 70.1 5.9 1089.5 Arthritis21. Januvia,Merck&Co. 64.6 27.6 133.8 Diabetes22. Restasis,Allergan 58.0 41.0 41.5 Chronicdryeye23. Vyvanse,Shire 58.0 84.6 -31.5 ADHD24. Trilipix,AbbottLaboratories 56.3 43.7 28.8 Highcholesterol25. Lunesta,DainipponSumitomoPharmaCo. 54.1 19.4 179.3 Sleepdisorder20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • >>HEALTH-CAREREFORM| October 17, 2011 | 9Sponsoredby:PHARMACEUTICAL MARKETINGPHARMACEUTICAL ADVERTISING BY MEDIUM IN 2010U.S.measured-mediaadspending of$4.3billionformedicinesandpharmaceuticalcompanies.Spot TV 2.4% Radio 1.0%Cable TV networks 12.7%Outdoor 0.1%Internet (display) 4.7%Newspapers 7.1%Syndicated TV 8.1%TV networks 31.5%Magazines 32.5%Source:KantarMedia.SeeP.5andP.7fornotesonmeasuredmedia.PresidentObama’shealth-carereformlaw,passedinMarch2010,isaloomingpillforinsurancecompanies,doctors,hospitalsandtheentirehealth-caresystem.Themaindrug-relatedshiftundertheAffordableCareActisthatthegovernment—alreadythebiggestpharmacustomer—maybecomeanevenbiggeroneasavastlylargerpercentageofAmericansbecomeinsured.Forpharmamarketers,that meansthegovernmentwillhavemoreinfluenceoverprescriptiondrugs.Onequestionishowoff-labeldrugusewillbecovered.Drugsareusedoff-labeltotreatmanydiseases.Thatmeansadrugisnotspecificallyapproved,orhasnotbeenthroughtherigorousapprovalprocess,foraparticularuse.TheAmericanCancerSocietysaysoff-labeluseiscommonintreatingcancer.Butitcanalreadybedifficulttogetaninsurertoreimburseorpayforanoff-labeldrugtreatment.“Thequestioniswhatarethepoliciesforoff-labeluse,”saidWaynePine,apharmaindustryconsultantandformerFDAchiefspokesman.“Atoneextreme,anditisanextreme,governmentcouldprohibitanyuseorreimbursementforaproductbeingusedofflabel.Thatisanextreme,ofcourse,andIdon’tthinktheywillendupthere.”Decisionsnowonoff-labelcoveragearemadebythegovernmentonacase-by-casebasis.Thatcouldcontinue,oranoverarchingpolicycouldbeestablished,hesaid.Thenextbiggestcustomerofpharmacompaniesafterthegovernmentistheprimarypayergroupofmanagedcareandinsurancecompanies.That’swherehealth-carereformtendstomovedecisionmaking,saidJohnKamp,executivedirector,CoalitionforHealthcareCommunication.“Thepharmabusinesshastorespondbylookingatitsnewestcustomers.TheFDArulesareaimedatregulatingwhatdrugcompaniescansaytodoctorsandconsumers,butthereisn’tmuchthinkingabouthowtointeractwithpayersandthegovernment,”hesaid.Moreover,marketerswillneedtoreachnewprescriptiondrugconsumers—themorethan30millionpeoplewhohadpreviouslybeenuninsured.Combinedwiththemorelimitedaccesstodoctors,notbyhealth-carereformbutbyhospitalpoliciesorsimplyphysicians’timeconstraints,pharmaseemstohavemorereasontoadvertisedirectlytoconsumers.“Pharmacompanieswillstilltrytoreachdoctorsthroughsalespeopleandprofessionalpublications,butalsointhesamewaytheyreachconsumers.DoctorswatchTV,too,”saidKennethGoldstein,presidentofKantarMedia’sCampaignMediaAnalysisGroup.“Westillliveinaworld,evenwiththeinternet,wherepeoplestillspendmoretimewatchingTV,andevenmoresowitholderpeople,TVdrawsbigeyes.”Pharma,however,willfaceanotherchallengeasthehealth-carereformactisestablishedbecausewhileitisanationallaw,somemoneyandadministrationarefiltereddownthroughthestates.“Onmultipleissuesandatmultiplelevelsofgovernment,pharmacompaniesaregoingtohavetobeinvolvedwithgovernmentrelations,”Mr.Goldsteinsaid.Therealsoaresomedirectcostsintheact,intheformofnewannualtaxestobeleviedatthepharmaindustry,paidbasedonmarketshare.Thosetaxesaresettobeginnextyearwith$2.8billiontobepaidin2012and2013;$3billionin2014through2016;$4billionin2017;$4.1billionin2018;and$2.8billionin2019andbeyond,accordingtotheKaiserFamilyFoundation.Ofcourse,thatisifhealth-carereformremainslaw.RecentcourtchallengestothereformactbystateshavemadetheirwaythroughthelocalandregionalcourtsandarelikelyheadedtotheSupremeCourt,withseveralstates,stategroupsandeventheObamaadministrationaskingrecentlyforareviewbythehighcourt.Manyquestionsremain.Howmuchoff-labelusewillbecovered?Whatrolewillthestatesplay?Willthenewlawsurvivehighcourtreview?20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • everyone’s looking online for health information.In fact,research shows that a majority of people turn to the webfirst when looking for health information. Not just at some point,but “first.” That means about 57% of the online population turnsto the internet before talking to their doctor,spouse,friends or eventheir mom when looking for information.And about 82% of peo-ple deem access to online tools and health information as “critical,”according to Kantar Media’s 2011 MARS Online Behavior Study.Physicians are also increasingly going online. Whether lookingfor the latest research or treatment information, 86% of medicalprofessionals read journals online, and another 80% use referencepublications on the internet, according to Kantar Media’s 2011MARS Physician Sources & Interactions Study.Hospitals use the internet to give information about their serv-ices, create patient groups and build wellness communities aroundtheir brands. Boston University Medical Center, for instance, hasdeveloped a strategy that includes online virtual patient advocatesto help reduce patient re-hospitalization after discharge.So it would seem that pharmaceutical marketers would also besomewhere in the mix,just as they are in the offline mix of health-care information. But in general, they’re not.Already a cautious industry, pharmaceutical marketers are con-cerned about violating regulations,crossing privacy lines or appear-ing too aggressive to consumers. They also tend not to be experi-enced in digital marketing. So the net effect for these marketers isthat they either can’t, or won’t, go where many people and medicalcommunities already are.Pharma companies do play some role online, of course. Manyplace paid search advertising,and others buy display ads on medicalcommunity web pages. They maintain branded drug websitesdetailingthingslikethedrug’susage,risksandrewards,forinstance.However, themoreforward-lookingone-to-onemarketingwrittenabout so much in other industries is virtually unheard of.“When I read stories about what hospitals and doctors are doingonline,I wonder why can’t pharma do similar kinds of things?”saidNed Russell, managing director of Publicis Groupe’s Saatchi &Saatchi Wellness. “When it comes to digital and social, because ofthings like adverse reporting, they generally just don’t do it.”Adverse reporting—theAdverse Event Reporting System—is aU.S. Food and Drug Administration program intended to monitornegative effects attributed to prescription drugs. Filing reports isvoluntary for health-care professionals and consumers. However,pharma marketers are mandated to report.The FDA website reads:“If a manufacturer receives an adverse event report,it is required tosend the report to FDA as specified by regulations.”The fear is that web communications, such as blog postings byvisitors to a pharma-hosted or -sponsored site or comments on apharma social-media page, could fall under that mandate.Several studies have shown that only a small percentage ofonline pharma-related comments met all the criteria requiring acompany to report. But the onus of monitoring and reporting haskept many pharmaceutical marketers from trying.10 | October 17, 2011 |WHITE PAPERTIME SPENT ON PRESCRIPTION-DRUG WEBSITESAdAgeaskedKantarMediaCompetetolookatwebtrafficandengagementonsitesforprescriptiondrugsfocusedonfiveconditions:arthritis,cancer,depression,diabetesandhighcholesterol.Siteselectionwaslimitedtowebsitesaveragingmorethan10,000monthlyuniquevisitorsfromAugust 2010toAugust2011.Thetablebelowshowsthetopthreeineachcategorybyaverageminutesperpagepersessionoverthesametimeperiod.1.Inminutes.Source:KantarMediaCompete.AdAgeDataCenteranalysis.AVERAGE AVERAGE AVERAGEMONTHLYUNIQUE TIMEONPAGE PAGEVIEWSRANK CONDITION/SITE VISITORS PERSESSION1PERSESSIONArthritis1 rituxan.com 26,282 4.48 4.752 hyalgan.com 16,384 4.09 2.353 celebrex.com 108,375 4.05 2.36Cancer1 herceptin.com 10,435 5.12 7.922 femara.com 16,683 4.41 8.453 xeloda.com 11,419 4.34 2.68Depression1 effexorxr.com 48,736 4.15 2.502 seroquelxr.com 174,962 4.06 2.453 amoryn.com 24,121 3.89 2.83Diabetes1 humalog.com 17,717 6.17 2.502 byetta.com 11,778 6.12 2.453 actos.com 34,686 4.69 2.83Highcholesterol1 lovaza.com 40,998 5.78 5.322 crestor.com 155,553 5.43 3.833 lipitor.com 198,815 4.46 2.10Web marketing challenges20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • | October 17, 2011 | 11Sponsoredby:PHARMACEUTICAL MARKETINGWhen Facebook changed its rules in August 2011 and requiredall Facebook pages to enable comments, some pharmaceutical mar-keters shut down their Facebook pages for just that reason. Othershave posted warnings and reserve the right to disable comments,although some noted that kind of policy can hamper the building oftrusting two-way relationships.Butstillothersaretryingandaregettingkudosforeffectiveness.Boehringer Ingelheim is often cited as a pharma example of theright way to do Facebook. Visitors land on a “welcome” page, ver-sus the typical straight to wall postings on most pages.On the welcome page, the pharma company explains itsFacebook mission and policies in a friendly casual manner.The pagereads in part: “We have enabled our wall for commenting becausewe want to hear from you! Help us to keep this wall interesting byactively contributing in the spirit it’s intended for but please respectthe following otherwise our lawyers will be mad at us.”Boehringer Ingelheim lists and offers a rationale for its postingpolicy:“The company reserves the right to remove any postings at itssole discretion (we work with serious medical conditions and wecan’t risk unmonitored or unverified medical advice being pub-lished).” A disclaimer/caution about not using the site as a substi-tute for professional medical advice adds:“We know a lot of doctorsand trust us—they know about health!”AstraZeneca is another drug maker attempting to connect in thesocial-media space. In 2011, it held the first pharma-hosted Twitterchat (on the subject of prescription savings plans) and continues tokeep an active Twitter voice.The drug maker also maintains a blog,Facebook page and YouTube channel.AstraZeneca laid out its position on social media in a 2010 whitepaper that said in part:“AstraZeneca believes that we have an obligation to participatein social media in a responsible way to help educate patients, care-givers,health-care providers and the general public.Our active par-ticipation can provide information to help ensure that patients getthe appropriate medicine at the right time and that it is taken in theright way.As we await FDA guidance and determine the appropri-atepathforwardforAstraZeneca,outreachtootherindividualswhoengage in this arena—patients, caregivers, health bloggers, mediastakeholders—simply makes sense; it has helped inform and shapeAstraZeneca’s perspective on key issues.”LACKOFGUIDELINESAdverse-reporting regulations create a challenge for pharma firmsin social and digital media that marketers in other industries don’tface. But it is the lack of digital guidelines that seems to frustratepharma marketers even more.TheFDAheldatwo-dayhearingwithphysicians,marketersandother industry experts regarding web and social-media advertisinginfall2009inWashington,D.C.,butnoguidelineshavebeenissuedfrom that. Most of the comments and notices issued by the FDAsince then have been vague and haven’t offered a specific timetable.An FDA spokeswoman in October 2011 said:“Policy and guid-ance development for promotion of FDA-regulated medical prod-ucts using the internet and social media tools are among our high-est priorities. Despite our limited resources and increasing work-load, we remain committed to this area in terms of both time andhuman resources.”The spokeswoman added:“It is difficult to provide a timeframefor the issuance of our guidances due to the extensive work andreview process, or ‘Good Guidance Practices,’ which ensures thatFDA’s stakeholders are provided well-vetted guidances articulatingFDA’s current thinking on a topic.”The FDA has identified these issues as “important to address”:responding to unsolicited requests; fulfilling regulatory require-ments when using tools associated with space limitations; fulfillingpost-marketing submission requirements; online communicationsfor which manufacturers, packers or distributors are accountable;use of links on the internet; and correcting misinformation.“We are developing multiple draft guidances to address thesetopicstobenefitindustryandthepublicbyensuringthatthesedraftguidances are meaningful and well thought out when they areissued,” the spokeswoman said.Source:KantarMedia.AdAgeDataCenteranalysis.Figuresexcludesearchandbroadbandvideo.Numbersrounded.LARGEST PHARMACEUTICAL INTERNET DISPLAY ADVERTISERSU.S.spendingbycompanyforcorporatepharmaceuticalcampaignsandprescriptiondrugs.Dollarsinmillions.INTERNET AD SPENDINGINTERNET AD SPENDINGPfizer Bristol-Myers Squibb Co.Eli Lilly & Co. Dainippon Sumitomo Pharma Co.Shire Amgen/PfizerMerck & Co. Abbott LaboratoriesAstraZeneca$28.6$27.5$22.2$17.3$13.1$64.0$24.5$45.9$21.8$52.2 Takeda Pharmaceutical Co.$10.3$8.8$8.6$8.1$6.9$7.2$1.8$3.5$2.5$1.82010 2009 2010 200920111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • 12 | October 17, 2011 |WHITE PAPERThe FDA has a tough job in regards to the web and social-mediaguidelines.Not only are new technologies constantly emerging,butthe import of the task—regulating drugs that affect people’s healthand well being—is not as easy as regulating laundry detergent orsoft drinks. Industry experts interviewed for this white paper dorealize and respect that. But they await formal guidance.“We’ve been holding our breath waiting for them to tell us whatwe can and cannot do,” said Buddy Scalera,VP-interactive contentand market research, WPP’s Ogilvy CommonHealth. “We try toapply the offline rules online, but that doesn’t always translate. …Some of the other guidance we do have comes from the reactionsof the FDA to something a marketer has done.”He is referring to warning letters the FDA sends to inform amarketer it has violated policy.For example,the FDA sent Novartisa letter in July 2010 requesting that it remove a Facebook sharewidget for leukemia treatment drug Tasigna because Novartis didnot disclose all risk information at the widget site. A link to moreinformation was not sufficient, the FDA stated in the letter.The FDA issued a less serious “untitled letter” (also called anotice of violation letter) to Pfizer in August 2011 about a Lipitorweb page where an “online resources” section mentioned otherPfizer drugs:Caduet,Chantix and Norvasc.The drugs listed includ-edlinkstomoreinformationbutnotafulllistofriskdisclosure.TheFDA deemed that disclosure insufficient.Those FDA communications indicate that when it comes to theweb, no shortcuts are allowed in explaining risks. Just like in tradi-tional-media advertising, it seems to say via these letters, a detaileddisclosure of risks must be presented.Meanwhile,some marketers and industry advocates are comingup with their own rules for web and social media.“Waiting for the stone tablet to come down from the mountainis probably not going to happen, so we will develop best practicesourselves,” said John Kamp, executive director of Coalition forHealthcare Communication, referring to the new Digital HealthCoalition. That group, made up of a broad swath of health-carecompany executives, is drafting its own best practices and plans toput them out for public comment by the end of 2011 with the goalof publishing the voluntary guidelines by the end of 2012.WEBANDSOCIALMEDIAAREFUTUREFORPHARMAThe coalition is pushing forward, despite no clearcut FDA guide-lines,becauseitbelievesthatpharmamustfindawaytousetheweband social media to connect with consumers.As is the case in manyindustries,the voice of the consumer is becoming an important partof the brand, and the era of one-way messaging is over.“Allofthesudden,companiesarelookingathealthcareinaverydifferent way than they used to.Social media and mobile health arejust triggers that are pushing it,” said Fabio Gratton, chief innova-tion officer at inVentiv Health’s Ignite Health.”The real opportuni-ty is to be a complete service provider.It’s drugs versus health care.”Mr. Gratton said there are two ways of thinking about thechanges in pharma and the web. One group is already out thereexperimenting—failing sometimes, but always trying—to reachconsumersinnewways.Theother,afraidoruninterestedinbecom-ing consumer-centric, will likely pull back and stick to drug R&D.No matter which direction a company goes in online marketing,two key web issues—privacy and brand safety—will be even moreimportant in the heavily regulated pharma industry.“There’s probably going to have to be a lot of opting in, and‘real’ informed consent, if you will,” said Mark Goldstone, pres-ident of Omnicom Group’s DDB Health. “But it’s not just thatpharma or health care is behind the times. It’s not a lacking ofwanting. It’s the delicacy of it.”You can see by spending patterns that drug firms are treadinglightly.Web spending is still a tiny part of pharma companies’ U.S.ad spending.About $203 million was spent on internet display adsin 2010 out of a total $4.3 billion, according to Kantar Media data.Pfizer,thetop-spendingpharmaat$967.5millionin2010measuredmedia, spent an estimated $28.6 million on internet ads, or 2.8%.DOCONSUMERSCARE?While pharma tends to sit cautiously on the sidelines, consumershave rushed ahead in searching the web for health information.However,the vast majority of consumers visit so-called non-brand-edwebsites—sourcesofinformationsuchasWebMD—ratherthanpharma branded websites (sites run by drug companies).In fourth-quarter 2010, of the 6.5 million unique visitors to allwebsites about cancer, only 276,000 (about 4.2%) were to brandedsites,accordingtoKantarMediaCompetedata.Compete also foundlow single-digit percentages for such other health conditions asdiabetes, depression, high cholesterol and rheumatoid arthritis.Another metric from Compete looks at the time spent on specificbranded drugs’ websites. Time spent varied from as little as abouttwo minutes per web session to as high as eight minutes.Thatmaynotseemlikealongtimetospendonasite.Butifyoutake into account the likely large volume of people who click awayfrom the page immediately, an “average time of four to five min-utes by any industry’s standards is not bad,” said OgilvyCommonHealth’s Mr. Scalera.“On a lot of consumer sites, two tothree minutes is average.”It’s also probably a more qualified or quality amount of timespent, Mr. Scalera said. By the time consumers go to a prescriptiondrug page,they have had symptoms,seen a doctor,likely were test-ed and have been prescribed a medicine that is now a part of theirlives either temporarily or permanently.So what’s a pharmaceutial marketer to do?While even the taintof FDA warning letters is a potential public relations problem,there is also the potential danger that too many warning letterscould lead to an FDA shutdown on marketing a drug while claimsare investigated.That represents not only lost revenue to the mar-keter,but also the loss of a drug a patient might need to treat a seri-ous medical condition.Insiders said drug companies are going to need to get creative—not only to maneuver through the digital-marketing landscape,butalso in the new lay of the land that will be the pharma industry.Nick Colucci, president-CEO of Publicis Groupe’s PublicisHealthcareCommunicationsGroup,citedanexampleofJohnson&Johnson’s Realize gastric band.J&J realized that the band alone doesn’t work because diet andbehavior modification are needed as well.The company created anonline tool that patients—and their doctors and surgeons—couldusetomonitordietandexercise.Afteroneyear,J&Jfoundthemorethe online tool was used, the more weight was lost and kept off.Said Mr. Colucci: “Clients are going to have to be more insight-ful and creative in thinking about what the product can do and gobeyond the obvious.”20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • a large percentage of medical condition-related conversationsin social media are “unbranded” (discussions where no specificbranded medication is mentioned). Across several therapeuticareas, only about 1% mention direct-to-consumer ad campaigns.Most discussions related to branded DTC campaigns take placeon blogs and forums.“The emotional and psychological toll of thecondition is touched upon frequently,” according to a KantarMedia Cymfony study.The second-quarter 2011 study examinedsocial-media conversations about brands and patient response toDTC campaigns.DTC posts increase with new campaigns; campaign frequency;launch of a key partnership with a celebrity; and unique story-lines. This trend is particularly visible in patient-generated postson Facebook and Twitter. When posts do mention specific cam-paigns, consumer sentiment tends to be negative—with largedoses of ridicule directed at the list of potential side effects.A Facebook post illustrates consumer confusion and concern:Regarding a branded campaign for what a poster called a psoriasis“cream”,the post noted,“it can increase your chances of cancer orheart attacks. Guess people will be sticking to the scratching.”Thepost was for an injectable medicine.Nevertheless,socialmediacanassistpharmamarketersandtheiragencies with insights into positioning,consumer response and tar-geting. A look at diabetes-related discussions (bottom) shows thevolume of posts and multiple brand mentions.For example,Lantuswas mentioned in social-media posts 40,998 times during 2009 and2010. Of those, 8% also mentioned Levemir.| October 17, 2011 | 13Sponsoredby:PHARMACEUTICAL MARKETINGSHARE OF DISCUSSIONAmongalldiabetesforumpostsin2009and2010.Branded discussion8%Unbranded diabetesdiscussion 92%Social media and healthDatashowmorediscussionofgeneralconditionsthanbrands.WhenDTCbrandedcampaignsarementioned,poststendtobenegativeinallformsofsocialmedia.RANK BRAND POSTS1. Lantus 40,998 - 7% 37% 42% 12% 7% 3% 4% 11% 4%2. Byetta 9,356 2% - 2 1 7 10 3 5 9 63. Levemir 9,152 8 2 - 8 1 2 1 1 1 24. Humalog 7,132 7 1 7 - 0 1 0 0 1 05. Actos 6,015 2 5 1 0 - 9 5 23 12 56. Januvia 4,313 1 5 1 0 6 - 3 5 8 267. Glucophage 3,877 0 1 0 0 3 3 - 4 6 28. Avandia 3,784 0 2 0 0 14 4 4 - 6 29. Amaryl 1,396 0 1 0 0 3 3 2 2 - 110. Janumet 1,279 0 1 0 0 1 8 1 1 1 -DIABETES-RELATED BRAND NAMES MENTIONED IN FORUMSRankedbynumberofpostsin2009and2010.Tableshowspercentageofpostsaboutabrandthatmentionedotherdiabetesdrugbrands.Source:KantarMediaCymfony.Figuresinredindicatehighestresonance.Resonance indicatesthepresenceofadiscussiontopicwithinadiscussionset.Forexample,resonanceofByettaagainstLantusmeanshowoftenByettaismentionedwithinallpostsaboutLantus. The%meanswhatpercentofLantuspostscontainamentionofByetta.LantusByettaLevemirHumalogActosJanuviaGlucophageAvandiaAmarylJanumetSource:KantarMediaCymfony.20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • 14 | October 17, 2011 |WHITE PAPERamericans submit almost four billion drug prescriptions everyyear, with an average of more than 12 prescriptions per person,according to the Kaiser Family Foundation.Whileagrowingnumberofthoseordersarefilledbymailorder,the vast majority of prescriptions are still filled at pharmacies,eithertraditional ones or increasingly at pharmacies inside supermarketsand mass merchants.And that makes the pharmacy, and the pharmacists themselves,a key cog in not only the pharmaceutical chain,but also in the mar-keting of prescription drugs and services. The pharmacy is quicklybecoming the hub ofAmerican health care.While people may see adoctororgotoahospitalthreetofourtimesayear,theylikelymakemore trips to the pharmacy for those prescriptions and refills alongwith other health-care needs.“Statistics say that as a member of the healthcare team, thepharmacist is seen more than any other member.That gives thema unique opportunity to interact with patients and customers,”saidMark McCoy, senior VP-brand planning at inVentiv Health’s Palioand a registered pharmacist for 30 years.The role of the pharmacist has been expanding, too, as patientssee their doctors less often and take on more decision making,as anaging population begins to take more and multiple drugs, and asgenerics become more popular but also more confusing as a choicefor consumers. The former reactionary role of pharmacists hasbecome a much more proactive one.Consider that many pharmacies offer vaccines and immuniza-tions,such as flu shots,which are now allowed to be given by phar-macists in all 50 states. Some pharmacies now also provide quickemergencycareinthegrowingtrendofminuteclinicsorreadycareoperations inside the store that can provide convenient visits andpain relief.It all adds up to a pharmacy renaissance,harkening backto the small trusted local pharmacies of yesteryear.Consumers do trust them,and in fact,pharmacists rank near thetop of the most-trusted professions at No. 3 on Gallup Poll’s annu-al Honesty and Ethics of Profession with 71% of people agreeingthat pharmacists are honest and ethical in 2010.Only nurses (81%)and military professionals (73%) ranked higher. Medical doctorswere No. 5 at 66%.Some retail pharmacy brands are recognizing that as well, andhave become more aggressive marketers, reaching out to con-sumers with messages of saving money, convenience and a readystaff of helpful, knowledgeable pharmacists.Target’s“Ask Us”campaign for its in-store pharmacies began in2009 and morphed into “Ask Me” this year, and is a great exampleof that. At the core of the message and creative work are Targetpharmacists. Clad in signature Target red shirts and traditionalpharmacist white jackets, they dispense friendly smiles along withthe encouragement to “Ask me anything about anything.”“We needed to drive awareness for our pharmacies. At thatpoint, we had won two or three J.D. Power awards, but the cate-gories more associated with Target are style and fashion,” said WillSetliff, senior VP-marketing, Target Corp. “With health care as anemergingbusinessforus,weneededtodevelopamessageandmar-keting that didn’t mimic the fashion side or other parts of our busi-ness.We already had these highly educated,passionate team mem-bers (in pharmacy), so we decided to build around them.”Pharmacy organizations also realize that the pharmacist is moreimportant than ever to consumers. The National Association ofChain Drug Stores promotes the pharmacist role as “medicationtherapy experts”and offers best-practice suggestions to its memberpharmacists in working directly with patients in medication thera-py management, or MTM. That plan includes reviewing medica-tions with patients, developing a personal medication record andaction plan for each patient, and working with doctors to resolvemedication-related problems.While many pharmacists already do those things,it is becomingmore structured.Target, for instance, is piloting a formal program,now testing in several stores, that uses MTM.“The expectation of what a pharmacist should be to customershas increased over the past few years,” said Jose Barra, senior VP-health and beauty, Target Corp. “Our pharmacists are more avail-able to guests,they take more time with each customer.We encour-age them to be proactive. They dispense advice on prescriptiondrugs, but also on over-the-counter drugs as well.” The wholemindset is rather than just helping customers get better, Targethelps them stay healthy, he said.Mr. Barra described the Target pharmacy guest profile as a widespectrum with the sweet spot the mom with two kids,who in somecases might also be providing care for aging parents. That’s whereprograms like its trademark ClearRx system—with easy-to-readlabels, simple patient info cards on the back and color-coded ringsPharmacies and pharmacistsFIVE MOST-VALUED SOURCES FORHEALTH-CARE INFORMATIONBythepercentofrespondentswhoanswered:“verymuch/somewhat.”Source:KantarMedia’s2011MARSOTC/DTCStudy,2011versus2002. Respondentswereaskedtoindicatethevalueofcertainsourcesforhealth-careinformation.2011 20021. Doctors 69.9% 76.2%2. Pharmacists 55.9% 52.9%3. Nurses,physicianassistants 55.1% 47.9%4. Friends, spouse,otherrelatives 53.2% 55.9%5. In-doctor’s-officeads,brochures,pamphlets,wallboards39.1% 47.4%20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • around the neck of the bottle (meant to distinguish each member ofthe household’s prescriptions)—won the Design of the Decadeaward from the Industrial Designers Society of America. The sys-tem works in multi-generational busy households and is easier forolder consumers to understand.RISE OF GENERICSWhether it is due to drugs going off patent or from pressure byhealth-care management companies to cut costs or by consumerslookingforlessexpensiveoptions,theuseofgenericdrugsisgrow-ing by leaps and bounds. In 2010, 72% of all prescriptions dis-pensed were generics, up from 68% the year before.Theriseingenericdrugshasplayedaroleintheriseofthephar-macist. With so many generics bearing complex chemical names,and even more about to flood the market, the potential for confu-sion is high. Pharmacists can fill that role of balancing price advan-tages with health advantages—and not just for prescription drugsbut for OTC as well.“Eighty-two percent of people say they buy the over-the-count-er drug recommended by their pharmacist. And pharmacists tendto favor prescription-drug-to-over-the-counter switches because oftheir visibility and long safety track records,” Palio’s Mr. McCoysaid.“Look at Zantac,Prilosec,Zyrtec—when a well-known brand-ed drug goes OTC, it allows the marketer to continue marketingunder the name.There is still value in that brand name.”AGGRESSIVE CAMPAIGNSWe’ve all seen, or been the target of, retail pharmacy efforts to getyour “dance card” of prescriptions. In the past, many differentpharmacies have offered cash back or other in-store discounts forswitching.And while some still do, the current trend in pharmacyadvertising is more about establishing trust and helping customersfigure out the ever-changing world of health care.CVS Pharmacy, for instance, is currently offering advice as itsbonus for new or transferred prescriptions. Those new customerscan get its Care 1on1 service, which is a personal review by yourlocal pharmacist to talk about “topics related to savings, safety andside effects.”Among the five retailers that spend the most on pharmacy-related ads, No. 1 Walgreen Co. increased spending a bit from 2009to 2010, but Nos. 2 and 3, CVS Caremark Corp. and WalmartStores, respectively, dropped spending by more than 30% each,according to Kantar Media data. (CVS and Walmart declinedrequests for interviews for this story.) However,RiteAid Corp.andTarget,theNo.4and5adspenders,respectively,bothincreasedtheirad spending fairly significantly. Supermarkets are excluded fromthis ad spending ranking. But pharmacies inside grocery storesaccount for about $13.3 billion in sales.Walmart, which sparked the initial pharmacy marketing warwith its $4 generic prescription promotions five years ago, stilloffers a $10 gift card for online prescription transfers with homedelivery. Its move, although controversial, forced mass-merchantpharmacy retailers—and eventually some drug stores—to makethe same offer.Rite Aid is finding success with its Wellness+ lifestyle market-ing and loyalty program. Rite Aid just launched its first condition-specificWellness+fordiabetesincollaborationwithWebMD,offer-ing free lifestyle management tools as well as a welcome packagewith $100 in savings. Meanwhile, Rite Aid’s crossover from phar-macy to other in-store shopping is high, with almost 90% of itsWellness+ card holders shopping both sides of the store.Its tagline,reflecting its take on the importance of a quality relationshipbetween pharmacy and customer is,“With us, it’s personal.”“We’ve got an aging population and, to be honest, an over-weight population. People are starting to have chronic conditionsthey need medication for. They go to the drugstore once a month,or even more,to pick up scrips.Now the retailer knows they can getcustomers to the store 12 times a year, whereas before it may haveonly been three or four times,” Mr. McCoy said.“It’s a real oppor-tunity to sell ‘front of the store,’ as it used to be called.”MakingdoctorappointmentsBuyingmedicationMonitoringmedicinescheduleMonitoringprogress ofconditionAdministeringmedicationResearchingmedicalinformation+15%+2%+30%+18% +28%+45%10,000 2010 2011Source:KantarMedia’s2011MARSOTC/DTCStudy.| October 17, 2011 | 15Sponsoredby:PHARMACEUTICAL MARKETINGBABY BOOMERS ARE TAKING ON NEW HEALTH-CARE RESPONSIBILITIESCaregivers(populationinthousands)forthose65orolderincreased8%in2011.Onaveragethesecaregiversare55;62%ofthemarefemale;62%aremarried.20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • 16 | October 17, 2011 |WHITE PAPERMOST-PRESCRIBED PHARMACEUTICALSRanked by total number of U.S. retail prescriptions, 2010 (numbers in millions).Source:SDI.DatafromAdvertisingAgesibling ModernHealthcare,June13,2011.Note:Manufacturersindicatedaremajoritymanufacturer.Numbersrounded.Formoreinformationaboutthedatausedtocompilethislist,contact:SDI,1SDIDrive,PlymouthMeeting,Pa.19462;610-834-0800;sdihealth.com;alsoSpecialProjects/ResearchEditorRebeccaMielcarski,rmielcarski@modernhealthcare.com.RETAILPRESCRIPTIONSINMILLIONSRANK PRESCRIPTIONDRUG,MANUFACTURER(S) 2010 2009 %CHANGE PRIMARYCONDITION(S)1. hydrocodone/acetaminophen,MallinckrodtPh.;WatsonPh. 122.8 120.3 2.1 Pain2. lisinopril,LupinPharmaceuticals 76.9 73.8 4.3 Highbloodpressure3. simvastatin,LupinPharmaceuticalsandTevaPharmaceuticals 76.8 73.2 4.9 Highcholesterol4. levothyroxine,MylanPharmaceuticals 68.2 63.0 8.2 Hypothyroidism5. amoxicillin,Sandoz 51.1 51.4 -0.6 Bacterialinfection6. amlodipinebesylate,MylanPharmaceuticalsandGreenstone 50.2 44.9 11.7 Highbloodpressure7. azithromycin,GreenstoneandSandoz 48.8 49.8 -2.1 Bacterialinfection8. alprazolam,Sandoz 46.2 44.5 3.9 Mentalhealth,anxiety9. hydrochlorothiazide,IvaxPharmaceuticals 45.8 46.2 -0.8 Highbloodpressure10. omeprazole,MylanPharmaceuticals 44.8 38.8 15.4 Gastroesophagealrefluxdisease11. metformin,TevaPharmaceuticalsandZydusPharmaceuticals 41.9 40.1 4.7 Diabetes12. Lipitor,Pfizer 37.5 42.3 -11.3 Highcholesterol13. furosemideoral,MylanPharma.andRanbaxyPharma. 36.6 36.6 -0.1 Highbloodpressure14. metoprololtartrate,MylanPharmaceuticals 34.7 34.9 -0.5 Highbloodpressure,angina15. atenolol,SandozandMylanPharmaceuticals 33.8 38.0 -11.0 Highbloodpressure,angina16. sertraline,Greenstone 33.4 30.7 8.9 Mentalhealth,depression17. metoprololsuccinate,ParPharm.Cos.andWatsonPharma. 32.2 28.8 11.9 Highbloodpressure18. zolpidemtartrate,TevaPharmaceuticals 29.7 30.6 -2.8 Mentalhealth,sleepdisorder19. oxycodone/acetaminophen,MallinckrodtPharmaceuticals 28.7 26.9 6.8 Pain20. citalopramHBr,TorrentPharmaceuticals 28.0 25.6 9.4 Mentalhealth,depressionCustomer service is important to shoppers at pharmacies, as aregood prices. Opportunities to speak with the pharmacy staff andbrief wait times for prescription refills improve satisfaction.The fifth annual pharmacy report from J.D. Power andAssociates released in September 2011 found that customers havehigherthaneverexpectationswhenitcomestopharmacyshoppingand performance.Last year, for instance, customer satisfaction increased when thewait time was less than seven minutes for a prescription. However,this year customer satisfaction decreased with wait time of justthree minutes for a prescription.“Customers are expecting more from their brick-and-mortarpharmacy—not just in terms of wait time,but also in terms of con-tactwiththepharmacistandpharmacystaff,”saidRickMillard,sen-iordirectorofthehealthcarepracticeatJ.D.PowerandAssociates,ina press release.“In fact,brick-and-mortar pharmacies are able to better differen-tiate themselves by offering additional services from the pharmacystaff,” he said. “These personal contacts may help distinguish thestore experience as satisfying for pharmacy customers.”20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • | October 17, 2011 | 17Sponsoredby:PHARMACEUTICAL MARKETINGPRESCRIPTIONS FILLED WITHGENERIC EQUIVALENTSPercentagesofprescriptionsfilledwithgenericsbytop10PBMs.Restat97.2%National Pharmaceutical Services79.5%Pharmacy Data Management76.7%informedRx76.0%Prescription Solutions71.9%Express Scripts71.6%CVS Caremark Corp.71.5%Medco Health Solutions71.0%Catalyst Rx71.0%Envision Pharmaceutical Services69.0%PBM DISTRIBUTIONPercentagesofprescriptionsfilledforallcompanieslisted.Mail order8.4%Retail network91.6%Pharmacy benefits managersRevenue,prescriptionsfilledandthedominanceofgenericsin2010.LARGEST PHARMACY BENEFIT MANAGERSRankedby2010revenuefromunbundledPBMservices. Dollarsinmillions.UNBUNDLEDRANK COMPANY PBMREVENUES1. MedcoHealthSolutionsFranklinLakes,N.J. $66,000.02. CVSCaremarkCorp. Woonsocket,R.I. 47,780.03. ExpressScriptsSt.Louis 44,973.24. PrescriptionSolutionsIrvine,Calif. 13,100.05. CatalystRxRockville,Md. 3,764.16. informedRxLisle,Ill. 1,841.67. EnvisionPharmaceuticalServices Twinsburg,Ohio 1,200.08. NationalPharmaceuticalServices Omaha,Neb. 1,100.09. RestatMilwaukee 1,087.4110. PharmacyDataManagementPoland,Ohio 917.6RANK COMPANY PRESCRIPTIONSFILLED1. ExpressScripts 753,900,0002. MedcoHealthSolutions 740,100,0003. CVSCaremarkCorp. 530,958,0004. PrescriptionSolutions 346,278,0005. HealthTrans 108,000,0006. CatalystRx 80,835,5547. Restat 51,258,7538. EnvisionPharmaceuticalServices 31,500,0009. informedRx 22,023,91410. PerformRx 20,000,000PRESCRIPTIONS FILLED BY PBMRankedbynumberofprescriptionsfilledin2010.Source:BusinessInsurancesurvey.FromSept.19,2011,report. 1.BusinessInsuranceestimate.BusinessInsuranceisasiblingpublicationofAdvertisingAge.VisitBusinessInsuranceResearch Center:businessinsurance.com/directories.20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • 18 | October 17, 2011 |WHITE PAPERMeasuringhowwellpharmaceuticalTVadsretainviewers.Retentionisbetterifviewershaveaconditionorknowsomeonewhodoes.Commercial tuneawayTuneaway:Commercialswiththehighesttuneaways.Smokingcessation,impotenceandanti-depressiongettunedoutmost.PHARMA COMMERCIALS: AUDIENCE TUNEAWAY AND RETENTIONRetention(CTI):Indexofcommercial’sabilitytokeepaudienceforspot’s30-secondduration.Overactivebladderandosteoporosisadsdobest.Chronic obstructive pulmonary disease 5.4Sleep disorder medicationsGout treatmentsDiabetes treatments5.5Psorasis treatments 5.5Arthritis medications 5.6Cholesterol medications 5.7Heart medications 5.7Contraceptive medications 5.9Anti-depression medications 6.1Impotence medications 6.4Smoking cessation aids 6.64.94.6Chronic dry eye treatments 94.1Diabetes treatments 94.0Mental health medications 93.9Overactive bladder treatments 94.8Osteoporosis medications 94.693.9Psoriasis treatments93.6Fibromyalgia pain treatments93.5Chronic obstructive pulmonary disease93.4Asthma medicationsArthritis medications 93.3Rosacea treatments 93.0ADHD medications 93.0Source:KantarMediaAudiences,whichusesreturnpathdata(RPD)fromabaseofhouseholdswithset-topboxes.tuneaway is the metric that defines the percentage of audiencewatchingaTVshowthatchangeschannelswhenacommercialstarts.As Jeff Boehme, chief research officer at Kantar Media AudiencesNorth America, explains: “The second an ad begins, what do peopledo?Weknowthatdramasgenerallyhavelesstunewaythancomedies.For commercials,the second an ad starts we can segment by categoryand by brand how well commercials are retaining viewers.”Tuneaway is high across most pharma categories.Kantar Mediadata show most channel changing occurs when stop smoking,impotence and anti-depression drug ads begin,with more than 6%of audience checking out.That’s more than double the average 3%tuneaway for all commercials.Only wrinkle removers and stomachmedications beat the average, at 2.2% and 2.5%, respectively.“There are a lot of reasons why people might tune out of an ad.While the media environment has the strongest influence on adavoidance, we see audiences reacting to specific creative messagesand topics in very deliberate ways,” Mr. Boehme said.“Wecanmeasurehowaudiencesrespond,andhowquicklytheychange the channel or stay tuned.”Kantar Media also measures overall retention—that is,not onlythat first second when people tuneaway, but the overall audiencethat stays with an ad for the full duration. Kantar Media takes thatmeasure of overall TV ad tuning and compares it with that TVshow’s total audience to calculate commercial tuning index (CTI).According to this metric, pharma marketers seem to have troubleretaining viewers.The industry average is about 95% or a 95 index, and onlyosteoporosis and overactive bladder commercials are close to that,atjust under 95%.Ads most likely to cause consumers to leave, withalmost 9% of audiences going elsewhere,are for contraceptives andhypotrichosis (eye-lash growing).“Effectiveness is about relevancy. If it’s a drug for asthma andyou or no one in your family has asthma, you’re more likely totune out,” Mr. Boehme said. “From an advertising perspective, itreally says they could do better at defining the target audience,andwe now have the data to know how.”20111017-WHTP--0002,0003,0004,0005,0006,0007,0008,0009,0010,0011,0012,0013,0014,0015,0016,0017,0018,0019,0020-NAT-CCI-AA_-- 10
    • Project1:Layout 1 10/7/11 11:56 AM Page 1
    • Project1:Layout 1 10/7/11 11:55 AM Page 1